Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Independent UN experts urge Yemen’s Houthis to free detained Baha'i followers
Antiques Roadshow guest receives staggering appraisal for gift he received years ago at college
Dunlap declared PGA Tour Champions winner after rain washes out final round
Paula Badosa says she and Stefanos Tsitsipas are no longer a love match
Sarah Jessica Parker divides opinion with enormous hat on set of And Just Like That
City traders fired after being caught having sex with a cleaner in the office after
First loss shouldn't take away from Jaime Munguia's potential
Wheel of Fortune fans left in a frenzy after contestant's embarrassing slip
Defending champion South Carolina to open season in Las Vegas against Michigan
Victory may be in sight for Starmer but the polls can be deceptive
Macron is making a surprise trip to New Caledonia amid deadly unrest and indigenous frustration
Floods in southern Brazil kill at least 60, with 101 people missing